Amlodipine increases the therapeutic potential of ravuconazole upon Trypanosoma cruzi infection.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorMachado, Yara Almeida-
Autor(es): dc.creatorBahia, Maria Terezinha-
Autor(es): dc.creatorCaldas, Ivo Santana-
Autor(es): dc.creatorMazzeti, Ana Lia-
Autor(es): dc.creatorNovaes, Rômulo Dias-
Autor(es): dc.creatorVilas Boas, Breno Raimundo-
Autor(es): dc.creatorSantos, Lorena Júnia de Souza-
Autor(es): dc.creatorMartins Filho, Olindo Assis-
Autor(es): dc.creatorMarques, Marcos José-
Autor(es): dc.creatorDiniz, Lívia de Figueiredo-
Data de aceite: dc.date.accessioned2025-08-21T15:55:07Z-
Data de disponibilização: dc.date.available2025-08-21T15:55:07Z-
Data de envio: dc.date.issued2021-11-21-
Data de envio: dc.date.issued2021-11-21-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/jspui/handle/123456789/13999-
Fonte completa do material: dc.identifierhttps://journals.asm.org/doi/10.1128/AAC.02497-19-
Fonte completa do material: dc.identifierhttps://doi.org/10.1128/AAC.02497-19-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1027435-
Descrição: dc.descriptionMining existing agents that enhance the therapeutic potential of ergosterol biosynthesis inhibitors (EBI) is a promising approach to improve Chagas disease chemotherapy. In this study, we evaluated the effect of ravuconazole, an EBI, combined with amlodipine, a calcium channel blocker, upon Trypanosoma cruzi experimental infection. In vitro assays confirmed the trypanocidal activity of both compounds in monotherapy and demonstrated an additive effect (sum of the fractional inhibitory concentration [FIC] 0.5) of the combined treatment without additional toxicity to host cells. In vivo experiments, using a murine model of the T. cruzi Y strain in a short-term protocol, demonstrated that amlodipine, although lacking trypanocidal activity, dramatically increased the antiparasitic activity of underdosing ravuconazole regimens. Additional analysis using long-term treatment (20 days) showed that parasitemia relapse until 60 days after treatment was significatively lower in mice treated with the combination (4 out of 14 mice) than ravuconazole monotherapy (10 out of 14 mice), even in the presence of immunosuppressant pressure. Furthermore, the combined therapy was well tolerated and protected the mice from mortality. The treatments also impacted on the cellular and humoral immune response of infected animals, inducing a reduction of serum cytokine levels in all ravuconazole-treated mice. Our findings demonstrate that amlodipine is efficacious in enhancing the antiparasitic activity of ravuconazole in an experimental model of T. cruzi infection and indicates a potential strategy to be explored in Chagas disease treatment.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectChagas disease-
Palavras-chave: dc.subjectCalcium channel blockers-
Palavras-chave: dc.subjectCombination therapy-
Palavras-chave: dc.subjectExperimental chemotherapy-
Palavras-chave: dc.subjectRepurposing-
Título: dc.titleAmlodipine increases the therapeutic potential of ravuconazole upon Trypanosoma cruzi infection.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.